<DOC>
	<DOCNO>NCT00380835</DOCNO>
	<brief_summary>The purpose study evaluate incidence cardiac toxicity amrubicin administer patient metastatic breast cancer .</brief_summary>
	<brief_title>Study Amrubicin With Without Herceptin Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Amrubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histological cytological diagnosis breast cancer . Metastatic recurrent disease , either HER2+ ( FISH+ 3+ IHC ) HER2 . Maximal dose prior adjuvant anthracycline : 300 mg/meters square doxorubicin equivalent . Relapse great one year trastuzumab adjuvantly ; two year follow adjuvant anthracycline therapy ( without trastuzumab ) . One prior chemotherapy metastatic breast cancer allow ( may include trastuzumab HER2+ patient ) , prior Doxil , adriamycin epirubicin metastatic breast cancer . At least 18 year age . ECOG Performance Status 0 , 1 , 2 . Adequate organ function include follow : Adequate bone marrow reserve . Cardiac : Left ventricular ejection fraction ( LVEF ) great equal 55 % MUGA . Negative serum pregnancy test time enrollment woman childbearing potential . Ability understand requirement study , provide write informed consent authorization use disclosure protect health information , agree abide study restriction return required assessment . Pregnant nursing woman . Concurrent anticancer therapy . Participation investigational drug study within 28 day prior study entry . Concurrent severe uncontrolled medical disease ( i.e. , active systemic infection , diabetes , uncontrolled hypertension , coronary artery disease , congestive heart failure , severe arrhythmia ) , opinion Investigator , would compromise safety patient compromise ability patient complete study . Symptomatic central nervous system metastasis . Patients asymptomatic brain metastasis allow . The patient must stable radiotherapy great equal 2 week corticosteroid great equal 1 week . History interstitial lung disease pulmonary fibrosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>metastatic breast cancer</keyword>
	<keyword>amrubicin</keyword>
</DOC>